9.48
전일 마감가:
$8.50
열려 있는:
$8.49
하루 거래량:
1.05M
Relative Volume:
0.25
시가총액:
$73.97M
수익:
-
순이익/손실:
$-6.42M
주가수익비율:
-1.6925
EPS:
-5.6013
순현금흐름:
$-7.45M
1주 성능:
-33.66%
1개월 성능:
+334.86%
6개월 성능:
-37.34%
1년 성능:
-59.31%
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
CRVO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CRVO
Cervomed Inc
|
9.48 | 73.97M | 0 | -6.42M | -7.45M | -5.6013 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
2024-12-06 | 개시 | ROTH MKM | Buy |
2024-12-05 | 개시 | H.C. Wainwright | Buy |
2024-09-18 | 개시 | Chardan Capital Markets | Buy |
2024-07-26 | 개시 | Morgan Stanley | Overweight |
2024-02-15 | 개시 | Canaccord Genuity | Buy |
2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
FY2025 EPS Estimates for CervoMed Lowered by Chardan Capital - Defense World
CervoMed (CRVO) Projected to Post Quarterly Earnings on Friday - Defense World
CervoMed (NASDAQ:CRVO) Given Buy Rating at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
CervoMed Announces Oral Presentation at 19th International - GlobeNewswire
CervoMed Inc. to Present Findings on Neflamapimod in Dementia with Lewy Bodies at AP/PD™ Conference 2025 - Nasdaq
New Clinical Data: CervoMed's Breakthrough Dementia Drug Results Revealed at Global Conference - StockTitan
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
CervoMed Stock: Extension Study Data In Dementia Is Potentially Exciting, With Caveats - Seeking Alpha
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Roth Capital Issues Negative Forecast for CervoMed Earnings - Defense World
Q1 Earnings Forecast for CervoMed Issued By Roth Capital - Defense World
Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts? - Insider Monkey
CervoMed reports FY24 EPS ($2.02), consensus ($1.85) - MSN
CervoMed Inc (CRVO) Reports Q4 Net Loss of $16.3 Million, Grant Revenue at $9.7 Million - GuruFocus.com
Roth Mkm Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World
CervoMed (NASDAQ:CRVO) Given New $21.00 Price Target at Canaccord Genuity Group - Defense World
Best Biotech Stocks To Watch Now – March 17th - Defense World
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
CervoMed price target raised to $20 from $15 at Roth MKM - TipRanks
Following A Monumental March, Can CRVO Keep The Rally Going In April? - RTTNews
CervoMed sees cash runway into mid-2026 - MSN
CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
CervoMed price target raised to $21 from $12 at Canaccord - TipRanks
CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now - Insider Monkey
Cervomed Inc. Faces Financial Hurdles Due to Regulatory Restrictions on Public Float - TipRanks
Small Cap Stocks To Watch NowMarch 13th - MarketBeat
Peering Into CervoMed's Recent Short Interest - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 -March 17, 2025 at 08:19 am EDT - Marketscreener.com
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
CervoMed's Breakthrough in Lewy Body Dementia Treatment Shows Promise in Latest Financial Report - StockTitan
Why CervoMed Inc. (CRVO) Soared Last Week? - Insider Monkey
These 10 Stocks Posted Double-, Triple-Digit Gains Last Week - Insider Monkey
Small Cap Stocks To Watch TodayMarch 12th - MarketBeat
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Capital One, CervoMed, HPE, Eaton, PepsiCo: Trending by Analysts - MSN
CervoMed (CRVO) Stock: 187% Weekly Surge Catches Analysts’ Attention - MoneyCheck
CervoMed (NASDAQ:CRVO) Raised to Buy at Jones Trading - Defense World
Biotech Stocks To Keep An Eye On – March 13th - Defense World
CervoMed (NASDAQ:CRVO) Stock Rating Upgraded by Chardan Capital - Defense World
CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program - Yahoo Finance
‘Turning point in dementia’—CervoMed stock skyrockets on promising dementia drug results - InvestorsObserver
We Think CervoMed (NASDAQ:CRVO) Can Afford To Drive Business Growth - Yahoo Finance
Best Biotech Stocks To Watch Now – March 12th - Defense World
CervoMed (NASDAQ:CRVO) Upgraded at Brookline Capital Management - Defense World
Medical Stocks To Keep An Eye On – March 12th - Defense World
FY2024 EPS Forecast for CervoMed Increased by Analyst - Defense World
CervoMed - The Pharma Letter
CervoMed's Dementia Study's 16-Week Data 'Compelling Enough To Move From Sidelines' Analyst Says - Benzinga India
Jones Trading lifts CervoMed stock rating, sets $15 target - Investing.com India
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):